• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Sorafenib in adjuvant setting: call for precise and personalized therapy.索拉非尼在辅助治疗中的应用：呼吁精准和个性化治疗。
Transl Gastroenterol Hepatol. 2016 Mar 16;1:13. doi: 10.21037/tgh.2016.03.13. eCollection 2016.
2
Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study.索拉非尼作为辅助治疗预防根治性手术后肝细胞癌早期复发的疗效：一项初步研究。
Hepatol Res. 2014 May;44(5):523-31. doi: 10.1111/hepr.12159. Epub 2013 Jun 13.
3
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.索拉非尼辅助治疗肝细胞癌切除术后或消融后（STORM）：一项 3 期、随机、双盲、安慰剂对照试验。
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
4
Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience.索拉非尼作为可切除肝细胞癌辅助治疗的单中心经验
J BUON. 2016 Sept-Oct;21(5):1189-1194.
5
Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.索拉非尼辅助治疗切除术后肝细胞癌患者：预测因素评估
Med Oncol. 2015 Apr;32(4):107. doi: 10.1007/s12032-015-0549-3. Epub 2015 Mar 7.
6
Evolving role of Sorafenib in the management of hepatocellular carcinoma.索拉非尼在肝细胞癌治疗中的角色演变
World J Clin Oncol. 2017 Jun 10;8(3):203-213. doi: 10.5306/wjco.v8.i3.203.
7
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.巴塞罗那临床肝癌C期肝细胞癌患者肝切除术后辅助使用索拉非尼。
World J Gastroenterol. 2016 Jun 21;22(23):5384-92. doi: 10.3748/wjg.v22.i23.5384.
8
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.索拉非尼或舒尼替尼作为术后辅助治疗用于有疾病复发高风险的中国局部进展期透明细胞肾细胞癌患者。
Urol Oncol. 2013 Nov;31(8):1800-5. doi: 10.1016/j.urolonc.2012.04.019. Epub 2012 May 31.
9
Supplementary Sorafenib Therapies for Hepatocellular Carcinoma-A Systematic Review and Meta-Analysis: Supplementary Sorafenib for Liver Cancer.索拉非尼辅助治疗肝细胞癌的系统评价和荟萃分析：索拉非尼治疗肝癌。
J Clin Gastroenterol. 2019 Aug;53(7):486-494. doi: 10.1097/MCG.0000000000001175.
10
Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.辅助性索拉非尼降低了肝细胞癌患者根治性切除术后的死亡率，延长了总生存期和复发后生存期：单中心经验
Biosci Trends. 2014 Dec;8(6):333-8. doi: 10.5582/bst.2014.01120.

引用本文的文献

1
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.辅助信迪利单抗治疗切除术后高危肝细胞癌的随机、对照、Ⅱ期临床试验
Nat Med. 2024 Mar;30(3):708-715. doi: 10.1038/s41591-023-02786-7. Epub 2024 Jan 19.
2
Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma.索拉非尼治疗晚期肝细胞癌的差异反应。
Biomedicines. 2022 Sep 14;10(9):2277. doi: 10.3390/biomedicines10092277.
3
Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma.基因组变化百分比和 7q 染色体扩增可预测晚期肝细胞癌对索拉非尼的反应。
Biomed J. 2021 Dec;44(6 Suppl 1):S73-S83. doi: 10.1016/j.bj.2020.07.001. Epub 2020 Jul 15.
4
Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma.肿瘤免疫微环境特征分析鉴定出 M0 巨噬细胞富集簇是肝细胞癌的一个不良预后因素。
JCO Clin Cancer Inform. 2020 Oct;4:1002-1013. doi: 10.1200/CCI.20.00077.

本文引用的文献

1
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.索拉非尼或安慰剂联合载多柔比星微球 TACE 治疗中晚期 HCC：SPACE 试验。
J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.
2
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.二甲双胍通过上调TIP30的表达来抑制索拉非尼在肝细胞癌中的促转移作用。
Cancer Sci. 2016 Apr;107(4):507-13. doi: 10.1111/cas.12885. Epub 2016 Feb 23.
3
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.索拉非尼辅助治疗肝细胞癌切除术后或消融后（STORM）：一项 3 期、随机、双盲、安慰剂对照试验。
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
4
Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14.让索拉非尼变得不可抗拒：对肝细胞癌治疗耐药机制进行体内筛选发现了丝裂原活化蛋白激酶14（Mapk14）。
Hepatology. 2015 May;61(5):1755-7. doi: 10.1002/hep.27739. Epub 2015 Mar 20.
5
Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.辅助性索拉非尼降低了肝细胞癌患者根治性切除术后的死亡率，延长了总生存期和复发后生存期：单中心经验
Biosci Trends. 2014 Dec;8(6):333-8. doi: 10.5582/bst.2014.01120.
6
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.pERK和VEGFR-2在晚期肝细胞癌中的表达及对索拉非尼治疗的耐药性
Liver Int. 2015 Aug;35(8):2001-8. doi: 10.1111/liv.12778. Epub 2015 Jan 22.
7
Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma.辅助性索拉非尼在高危肝细胞癌肝移植受者中的应用。
J Transplant. 2014;2014:913634. doi: 10.1155/2014/913634. Epub 2014 Apr 10.
8
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.人源和鼠源 VEGFA 扩增型肝癌对索拉非尼治疗高度敏感。
Cancer Discov. 2014 Jun;4(6):730-43. doi: 10.1158/2159-8290.CD-13-0782. Epub 2014 Mar 31.
9
Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.肝细胞癌：III 期失败的原因及试验设计的新视角。
Clin Cancer Res. 2014 Apr 15;20(8):2072-9. doi: 10.1158/1078-0432.CCR-13-0547. Epub 2014 Mar 3.
10
Management of sorafenib-related adverse events: a clinician's perspective.索拉非尼相关不良反应的管理：临床医生的视角。
Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16. doi: 10.1053/j.seminoncol.2014.01.001. Epub 2014 Jan 9.

Sorafenib in adjuvant setting: call for precise and personalized therapy.

作者信息

Zhang Wei

机构信息

Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.

出版信息

Transl Gastroenterol Hepatol. 2016 Mar 16;1:13. doi: 10.21037/tgh.2016.03.13. eCollection 2016.

DOI:10.21037/tgh.2016.03.13
PMID:28138580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5244768/
Abstract
摘要